| __timestamp | Halozyme Therapeutics, Inc. | MiMedx Group, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 79696000 | 7050000 |
| Thursday, January 1, 2015 | 93236000 | 8413000 |
| Friday, January 1, 2016 | 150842000 | 12038000 |
| Sunday, January 1, 2017 | 150643000 | 17900000 |
| Monday, January 1, 2018 | 150252000 | 15765000 |
| Tuesday, January 1, 2019 | 140804000 | 11140000 |
| Wednesday, January 1, 2020 | 34236000 | 11715000 |
| Friday, January 1, 2021 | 35672000 | 17344000 |
| Saturday, January 1, 2022 | 66607000 | 22829000 |
| Sunday, January 1, 2023 | 76363000 | 12665000 |
| Monday, January 1, 2024 | 79048000 |
Data in motion
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Halozyme Therapeutics, Inc. and MiMedx Group, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Halozyme consistently outspent MiMedx, with its R&D expenses peaking in 2016 and 2017 at over 150% more than MiMedx's highest expenditure year. Notably, Halozyme's spending dipped significantly in 2020, aligning with global economic challenges, but rebounded by 2023. Meanwhile, MiMedx's R&D investment showed a steady increase, reaching its zenith in 2022. This divergence in spending strategies highlights the varied paths companies take in pursuit of innovation. As the biotech landscape evolves, these financial commitments will likely play a pivotal role in shaping future breakthroughs.
Who Prioritizes Innovation? R&D Spending Compared for Zoetis Inc. and Halozyme Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Intra-Cellular Therapies, Inc. and Halozyme Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Halozyme Therapeutics, Inc. and Pharming Group N.V.
Halozyme Therapeutics, Inc. vs Xenon Pharmaceuticals Inc.: Strategic Focus on R&D Spending
R&D Spending Showdown: Halozyme Therapeutics, Inc. vs Perrigo Company plc
R&D Insights: How Halozyme Therapeutics, Inc. and ImmunityBio, Inc. Allocate Funds
R&D Insights: How Halozyme Therapeutics, Inc. and Mesoblast Limited Allocate Funds
R&D Insights: How Halozyme Therapeutics, Inc. and Dynavax Technologies Corporation Allocate Funds
Research and Development Investment: PTC Therapeutics, Inc. vs MiMedx Group, Inc.
Comparing Innovation Spending: Celldex Therapeutics, Inc. and MiMedx Group, Inc.
Research and Development Investment: BioCryst Pharmaceuticals, Inc. vs MiMedx Group, Inc.
R&D Spending Showdown: Xencor, Inc. vs MiMedx Group, Inc.